% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Brown:155708,
      author       = {Brown, Emmeline E and Blauwendraat, Cornelis and Trinh,
                      Joanne and Rizig, Mie and Nalls, Mike A and Leveille,
                      Etienne and Ruskey, Jennifer A and Jonvik, Hallgeir and Tan,
                      Manuela M X and Bandres-Ciga, Sara and Hassin-Baer, Sharon
                      and Brockmann, Kathrin and Infante, Jon and Tolosa, Eduardo
                      and Ezquerra, Mario and Ben Romdhan, Sawssan and
                      Benmahdjoub, Mustapha and Arezki, Mohamed and Mhiri, Chokri
                      and Hardy, John and Singleton, Andrew B and Alcalay, Roy N
                      and Gasser, Thomas and Grosset, Donald G and Williams, Nigel
                      M and Pittman, Alan and Gan-Or, Ziv and Fernández-Santiago,
                      Rubén and Brice, Alexis and Lesage, Suzanne and Farrer,
                      Matthew and Wood, Nicholas and Morris, Huw R},
      collaboration = {Consortium, International Parkinson Disease Genomics},
      title        = {{A}nalysis of {DNM}3 and {VAMP}4 as genetic modifiers of
                      {LRRK}2 {P}arkinson's disease.},
      journal      = {Neurobiology of aging},
      volume       = {97},
      issn         = {0197-4580},
      address      = {Amsterdam [u.a.]},
      publisher    = {Elsevier Science},
      reportid     = {DZNE-2021-00876},
      pages        = {148.e17 - 148.e24},
      year         = {2021},
      abstract     = {The LRRK2 gene has rare (p.G2019S) and common risk variants
                      for Parkinson's disease (PD). DNM3 has previously been
                      reported as a genetic modifier of the age at onset in PD
                      patients carrying the LRRK2 p.G2019S mutation. We analyzed
                      this effect in a new cohort of LRRK2 p.G2019S heterozygotes
                      (n = 724) and meta-analyzed our data with previously
                      published data (n = 754). VAMP4 is in close proximity to
                      DNM3, and was associated with PD in a recent study, so it is
                      possible that variants in this gene may be important. We
                      also analyzed the effect of VAMP4 rs11578699 on LRRK2
                      penetrance. Our analysis of DNM3 in previously unpublished
                      data does not show an effect on age at onset in LRRK2
                      p.G2019S carriers; however, the inter-study heterogeneity
                      may indicate ethnic or population-specific effects of DNM3.
                      There was no evidence for linkage disequilibrium between
                      DNM3 and VAMP4. Analysis of sporadic patients stratified by
                      the risk variant LRRK2 rs10878226 indicates a possible
                      interaction between common variation in LRRK2 and VAMP4 in
                      disease risk.},
      keywords     = {Age of Onset / Aged / Cohort Studies / Dynamin III:
                      genetics / Epistasis, Genetic: genetics / Female / Genetic
                      Association Studies / Genetic Predisposition to Disease:
                      genetics / Genetic Variation: genetics / Humans /
                      Leucine-Rich Repeat Serine-Threonine Protein Kinase-2:
                      genetics / Linkage Disequilibrium: genetics / Male / Middle
                      Aged / Parkinson Disease: epidemiology / Parkinson Disease:
                      ethnology / Parkinson Disease: genetics / R-SNARE Proteins:
                      genetics / Risk / Genetic modifiers (Other) / Leucine-rich
                      repeat kinase 2 (Other) / Parkinsonism (Other) /
                      Parkinson’s disease (Other) / R-SNARE Proteins (NLM
                      Chemicals) / VAMP4 protein, human (NLM Chemicals) / LRRK2
                      protein, human (NLM Chemicals) / Leucine-Rich Repeat
                      Serine-Threonine Protein Kinase-2 (NLM Chemicals) / Dynamin
                      III (NLM Chemicals)},
      cin          = {AG Gasser},
      ddc          = {610},
      cid          = {I:(DE-2719)1210000},
      pnm          = {353 - Clinical and Health Care Research (POF4-353)},
      pid          = {G:(DE-HGF)POF4-353},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:32873436},
      pmc          = {pmc:PMC7762821},
      doi          = {10.1016/j.neurobiolaging.2020.07.002},
      url          = {https://pub.dzne.de/record/155708},
}